Showing results (5591-5600 of 5,703) with videos related to

Sort By:
Pageof 571
The Oncologist|March 15, 2025
Aumolertinib plus chemotherapy as first-line treatment for advanced NSCLC with EGFR exon 19 deletion or exon 21 L858R: a phase II trialYanwei Li, Chenguang Li, Xiaoliang Zhao, et al.
The Oncologist|April 15, 2025
Pancreatic enzyme replacement therapy in advanced adenocarcinoma of the pancreas improved overall survival: a retrospective, single institution studyVincent J Picozzi, Margaret T Mandelson, Anas Najjar, et al.
The Oncologist|April 26, 2025
Medical accuracy of artificial intelligence chatbots in oncology: a scoping reviewDavid Chen, Kate Avison, Saif Alnassar, et al.
The Oncologist|March 28, 2025
Geographic disparities in gastrointestinal oncology research: a focus on trial availability in ItalyMaurizio Polignano, Nicola Carella, Ornella Rotolo, et al.
The Oncologist|April 12, 2025
Epidemiology characteristics and clinical outcomes of composite Hodgkin lymphoma and diffuse large B-cell lymphoma using machine learningAilin Zhao, Xu Sun, Weishi Cheng, et al.
The Oncologist|June 15, 2023
Neoadjuvant Talazoparib in Patients With Germline BRCA1/2 Mutation-Positive, Early-Stage Triple-Negative Breast Cancer: Results of a Phase II StudyJennifer K Litton, J Thaddeus Beck, Jason M Jones, et al.
The Oncologist|June 6, 2023
A Survey of Practice Patterns for Clinical Nodal Staging Prior to Neoadjuvant Chemotherapy in Breast CancerHan-Byoel Lee, Kyung-Hun Lee, Seok Hyun Song, et al.
The Oncologist|June 1, 2023
A Phase I Trial of the Dual MET Kinase/OCT-2 Inhibitor OMO-1 in Metastatic Solid Malignancies Including MET Exon 14 Mutated Lung CancerMelinda A Pruis, Matthew G Krebs, Ruth Plummer, et al.
The Oncologist|February 20, 2026
ECOG 6293: Phase II Study of Raltitrexed in Advanced Colorectal CancerChengwei Peng, Paul Catalano, John Zalcberg, et al.
The Oncologist|February 25, 2026
Predictive Modeling of Treatment-Related Thyroid Dysfunction and Prognostic Implication in Advanced Nasopharyngeal Carcinoma With PD-1 InhibitorsYubin Hu, Xinyi Hong, Yi Li, et al.
Pageof 571